rucaparib - Robuta Search

https://www.cancerresearchuk.org/about-cancer/treatment/drugs/rucaparib Rucaparib (Rubraca) | Cancer information | Cancer Research UK Rucaparib is a type of targeted drug. It is a treatment for ovarian cancer. Find out about how you have it, possible side effects and other important... cancer information rucaparib rubraca research uk https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rucaparib-camsylate Definition of rucaparib camsylate - NCI Drug Dictionary - NCI Find technical definitions and synonyms by letter for drugs/agents used to treat patients with cancer or conditions related to cancer. Each entry includes... definition of rucaparib camsylate nci drug dictionary https://www.hmpgloballearningnetwork.com/site/onc/fda-approval/fda-approves-rucaparib-brca-mutated-metastatic-castration-resistant-prostate FDA Approves Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Based on results from the TRITON3 study, the FDA granted approval to rucaparib for previously treated patients with deleterious BRCA mutation-associated... fda approves rucaparib brca https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-adding-immunotherapy-to-rucaparib-for-ovarian-cancer-that-has-come-back-centurion A trial looking at adding immunotherapy to rucaparib for ovarian cancer that has come back... This trial is looking at adding nivolumab to rucaparib to improve treatment for ovarian cancer. https://www.aacr.org/about-the-aacr/newsroom/news-releases/maintenance-therapy-with-rucaparib-shows-clinical-responses-in-a-subgroup-of-patients-with-pancreatic-cancer/ Maintenance Therapy With Rucaparib Shows Clinical Responses in a Subgroup of Patients With... Nov 30, 2019 - Maintenance Therapy With Rucaparib Shows Clinical Responses in a Subgroup of Patients With Pancreatic Cancer maintenance therapy https://www.rcsb.org/structure/4RV6 RCSB PDB - 4RV6: Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparib Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparib